πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 379 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9222091

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9212364

Compositions and methods for inhibiting expression of mutant EGFR gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9206421

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gen

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9200282

Compositions and methods for inhibiting expression of an RNA from west nile virus

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9200281

Conserved HBV and HCV sequences useful for gene silencing

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9198983

Compositions and methods for inhibiting expression of Mylip/Idol gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9198972

Monomers and oligonucleotides comprising cycloaddition adduct(s)

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9198927

Targeting opposite strand replication intermediates of single-stranded viruses by RNAI

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9187747

RNAi modulation of ApoB and uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9187746

Dual targeting siRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9175290

Compositions and methods for inhibiting expression of TMPRSS6 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9133461

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9133454

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9127274

Serpinc1 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9127277

Methods and compositions for prevention or treatment of RSV infection

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9101643

Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9102938

2β€² and 5β€² modified monomers and oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9090895

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9074213

Compositions and methods for inhibiting expression of a target gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9061063

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9062310

Compositions and methods for inhibiting expression of factor VII gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9057069

Compositions and methods for inhibiting expression of Eg5 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9035041

Process for triphosphate oligonucleotide synthesis

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9029525

Compositions and methods for inhibiting expression of GSK-3 genes

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted